Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

A Sanofi official told lawmakers the company ... Only Metformin, another diabetes drug, was prescribed more frequently in 2023. Hal Andrews, CEO at Trilliant Health, said as new drugs soared ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

Sales of the drug in the United States rose 19.1% ... Tzield, approved to delay the onset of type I diabetes, was added to Sanofi’s portfolio with the 2023 acquisition of Provention Bio.